Caplin Point Laboratories has fixed September 18, 2026, as the record date for its 35th Annual General Meeting (AGM). The Board of Directors approved this timeline during a meeting held on August 12, 2026, ensuring shareholders holding equity shares on the specified date are eligible to attend the meeting and vote on resolutions. This determination also establishes the eligibility criteria for the payment of any final dividend declared for the financial year 2025-26.

The AGM is scheduled to take place on September 25, 2026. Shareholders must hold equity shares with a face value of ₹2 each in their demat accounts or physical holdings as of the close of business on the record date to participate in the proceedings. This procedural step is critical for investors seeking to exercise their voting rights or receive dividend entitlements, if approved by the shareholders during the meeting.

Key Dates and Details

The announcement was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company notified both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Ltd (NSE) regarding the intimation. Venkatram G, General Counsel & Company Secretary of Caplin Point Laboratories, signed the disclosure document.

What This Means for Investors

For retail and institutional investors, the record date acts as the cutoff for dividend entitlements. Any shares sold after September 18, 2026, will not carry the right to the final dividend for FY25-26, while shares purchased before this date will retain that entitlement. Investors should ensure their shareholdings are updated in their demat accounts prior to the record date to avoid any discrepancies in eligibility.

The final dividend amount, if declared, will be determined during the AGM on September 25, 2026. The company has not yet disclosed the proposed dividend per share, leaving the exact payout subject to shareholder approval at the upcoming meeting.

Caplin Point Laboratories delivered strong financial performance for Q1 FY27, reporting a consolidated net profit of ₹179.09 crore, an 18.8% increase from ₹150.76 crore in Q1 FY26. The company's total revenue climbed 20.7% year-on-year to ₹643.91 crore, supported by accelerated contributions from its US operations and steady expansion in Latin America. This growth trajectory underscores the effectiveness of its dual-market strategy, balancing high-margin regulated markets with volume-driven emerging economies.

The Board of Directors, meeting on August 12, 2026, approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Statutory Auditors, Brahmayya & Co., who issued a limited review report pursuant to Standard on Review Engagements (SRE) 2410. The Board also recommended a final dividend of ₹4 per equity share (200%) for the financial year ended March 31, 2026, subject to shareholder approval at the forthcoming Annual General Meeting (AGM).

Financial Performance Highlights

The company's operational efficiency improved alongside top-line growth, as confirmed per the company statement, with EBITDA rising 23.0% year-on-year to ₹247.0 crore and EBITDA margin expanding to 38.4% from 37.7%. Profit before tax increased by 22.1% to ₹225.23 crore. Basic earnings per share (EPS) grew 15.8% to ₹23.27 from ₹20.10 in the corresponding quarter of the previous year.

Gross margin stood at 59.8% in Q1 FY27, slightly down from 61.7% in Q1 FY26. The company maintained a robust balance sheet, with free cash reserves at ₹1,502 crore and total liquid assets reaching ₹2,875 crore as of June 30, 2026.

US Operations and Strategic Developments

The US market emerged as a key growth driver, with total revenue from the segment reaching ₹137 crores in Q1 FY27, representing a 26% increase year-on-year. Caplin Point Steriles Limited (CSL), the subsidiary responsible for US operations, continues to drive this momentum with 60 approved ANDAs and a pipeline of over 40 products under filing or advanced development. CSL has launched 38 products in the US so far, with plans to introduce 12 more in FY27. The company also secured emergency tenders worth $7 million across Central America and $12 million in Chile, reinforcing its presence in Latin America.

In leadership developments, the Board approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for two years, effective August 25, 2026. Additionally, Mr. D. Muralidharan was appointed as Whole-Time Director, effective August 12, 2026, continuing his role as Chief Financial Officer. Both appointments require shareholder approval at the AGM scheduled for September 25, 2026.

What the Numbers Show

The divergence between gross margin contraction (59.8% vs 61.7%) and EBITDA margin expansion (38.4% vs 37.7%) suggests that while input costs or product mix may have pressured initial margins, operational leverage and cost controls at the operating level successfully protected profitability. This indicates disciplined execution in managing overheads despite aggressive capacity expansion initiatives, including new facilities in Puducherry and Chennai aimed at doubling existing capacities by Q1 FY28.